Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II randomized double-blind placebo-controlled study of RLA-23174 in chronic kidney disease
CTR20252194Phase 2Active
- Sponsor
- Yingli Pharma
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of RLA-23174 in chronic kidney disease (CKD), sponsored by Yingli Pharma. Started Apr 2026; status: active.
02
Drugs
RLA-23174
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on CTR20252194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252194.